Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT06071013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06071013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Lead sponsor
China Medical University Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2024
Completion date
August 27, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, egfr-tki resistant mutation, non-small cell lung cancer